Evidence map›Paper›PMID 40427619›Full record

ArticleBiomolecules2025

The Hepatoprotective Properties of Gentiopicroside, Sweroside, and Swertiamarin Against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Anthony O Boateng, Vinood B Patel, S W Annie Bligh

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anthony O BoatengSchool of Science, Faculty of Engineering & Science, University of Greenwich, Central Avenue, Chatham, Kent ME4 4TB, UK.ORCID 0000-0002-4110-5234
Vinood B PatelSchool of Life Science, College of Liberal Arts and Science, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.ORCID 0000-0001-9334-2525
S W Annie BlighS. K. Yee School of Health Sciences, Saint Francis University, Hong Kong, China.

Funding

Ghana Education Trust Fund 0000000
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disease characterised by the accumulation of fat in the liver. It is estimated that 30-38% of the world's adult population have MASLD, making it the most prevalent global chronic liver disease. Due to a lack of a therapy for MASLD, treatment has been mainly focussed on managing the conditions associated with the disease such as obesity, diabetes mellitus, and hyperlipidaemia. This study aimed to investigate the role played by

Indexed as

Fatty LiverIridoid GlucosidesProtective AgentsPyronesApoptosisCell SurvivalGentianaHepatocytesHep G2 CellsHumansReactive Oxygen SpeciesgentiopicrosideIridoid GlucosidesProtective AgentsPyronesReactive Oxygen Speciesswerosideswertiamaringentiopicrosidehepatoprotectivephytochemicalssilymarinswerosideswertiamarin

Identifiers

PMID40427619
PMCPMC12109968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.